EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Placebo-response inflation in supportive oncology symptom trials: mechanisms, methodological challenges, and design implications

Mellar P Davis, Boris Kiselev

Supportive Care in Cancer · 2026-10 · 34 (10)

DOI: 10.1007/s00520-026-11218-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Supportive Care in Cancer, online erschienen am 12.09.2026. Verfasst von Mellar P Davis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Palliative Medicine, Division of Supportive Oncology, Atrium Health, Charlotte, NC, USA. Mellar.Davis@advocatehealth.org. Hauptthemen laut MEDLINE: Placebo Effect, Palliative Care, Neoplasms, Research Design. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Placebo-response inflation is increasingly recognized as an important determinant of treatment-placebo separation in symptom-focused clinical trials. This issue is particularly relevant in supportive oncology and palliative care, where primary outcomes are frequently patient-reported and may be influenced by expectancy, symptom variability, trial conduct, disease trajectory, and regression to the mean.

Objectives

To examine the major mechanisms contributing to placebo-response inflation in symptom-focused clinical trials and evaluate their implications for supportive oncology and palliative care research.

Methods

This narrative methodological review and conceptual synthesis examined evidence from meta-analyses, meta-regressions, methodological reviews, and cancer symptom-management studies addressing placebo-arm improvement, assay sensitivity, operational trial characteristics, expectancy effects, blinding integrity, regression to the mean, symptom variability, and disease-related moderators. Evidence was organized around mechanistic themes relevant to symptom-focused clinical trials.

Results

Evidence across multiple therapeutic domains indicates that placebo-arm improvement is influenced by operational factors such as site number and recruitment density, psychological factors including expectancy and blinding integrity, statistical factors such as regression to the mean, and disease-related moderators including symptom chronicity, baseline symptom burden, and illness trajectory. Studies conducted in patients with cancer demonstrate that placebo-arm improvement can be clinically meaningful in symptom-management trials. These mechanisms may converge in supportive oncology and palliative care research, where subjective endpoints, fluctuating symptoms, multicenter recruitment, and expectancy-sensitive interventions are common. Collectively, the evidence suggests that placebo-response inflation should be viewed as a design-sensitive and potentially measurable determinant of assay sensitivity rather than as nonspecific background variability.

Conclusions

Placebo-response inflation represents an important methodological challenge in supportive oncology trials. Greater attention to recruitment density, site quality, participant expectations, blinding integrity, symptom stability, repeated baseline assessments, and disease trajectory may improve trial sensitivity and enhance the ability to distinguish true therapeutic benefit from nonspecific symptom improvement. Incorporating a mechanism-based understanding of placebo response into trial design may improve the evaluation of symptom-directed interventions in supportive oncology and palliative care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Placebo EffectPalliative CareNeoplasmsResearch DesignClinical Trials as TopicHumans

Stichwörter der Autor:innen

Assay sensitivityClinical trialsExpectancyPalliative carePlacebo responseRegression to the meanSupportive oncologySymptom management

Autor:innen und Institutionen

  • Oncology Palliative Medicine, Division of Supportive Oncology, Atrium Health, Charlotte, NC, USA. Mellar.Davis@advocatehealth.org.
  • Section of Psycho-Oncology, Department of Supportive Oncology, Atrium Health, Charlotte, NC, USA.

Zitieren

APA

Davis, M. P., & Kiselev, B. (2026). Placebo-response inflation in supportive oncology symptom trials: mechanisms, methodological challenges, and design implications. Supportive Care in Cancer, 34(10). https://doi.org/10.1007/s00520-026-11218-4

Vancouver

Davis MP, Kiselev B. Placebo-response inflation in supportive oncology symptom trials: mechanisms, methodological challenges, and design implications. Supportive Care in Cancer. 2026;34(10). doi:10.1007/s00520-026-11218-4

BibTeX
@article{Davis2026,
  author = {Davis, Mellar P and Kiselev, Boris},
  title = {Placebo-response inflation in supportive oncology symptom trials: mechanisms, methodological challenges, and design implications},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {10},
  doi = {10.1007/s00520-026-11218-4}
}
Kostenlos starten →